Neothetics is a San Diego based clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market.

Our initial focus is on localized fat reduction and body contouring. Our lead product candidate, LIPO-202, is a proprietary first-in-class injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Our studies suggest that salmeterol xinafoate activates ß2 -adrenergic receptors on fat cells, triggering the body’s natural process of metabolizing stored triglycerides (fat) resulting in a reduction in size and volume of the fat cells in the treatment area without damage of nearby tissues.